Enanta Pharmaceuticals Inc’s recently made public that its President and CEO Luly Jay R. acquired Company’s shares for reported $0.26 million on Feb 12 ’25. In the deal valued at $5.69 per share,45,000 shares were bought. As a result of this transaction, Luly Jay R. now holds 846,638 shares worth roughly $ 6.04 million.
Then, Kieffer Tara Lynn sold 2,283 shares, generating $18,401 in total proceeds. Upon selling the shares at $8.06, the Chief Product Strategy Officer now owns 29,305 shares.
Before that, Luu Brendan sold 2,283 shares. Enanta Pharmaceuticals Inc shares valued at $18,401 were divested by the Chief Business Officer at a price of $8.06 per share. As a result of the transaction, Luu Brendan now holds 36,047 shares, worth roughly $0.26 million.
JP Morgan downgraded its Enanta Pharmaceuticals Inc [ENTA] rating to an Underweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Hold”. H.C. Wainwright began covering ENTA with “Buy” recommendation on December 09, 2022. Evercore ISI revised its rating on July 06, 2022. It rated ENTA as “an Outperform” which previously was an “an In-line”.
Price Performance Review of ENTA
On Friday, Enanta Pharmaceuticals Inc [NASDAQ:ENTA] saw its stock fall -4.80% to $7.14. Over the last five days, the stock has gained 45.71%. Enanta Pharmaceuticals Inc shares have risen nearly 24.17% since the year began. Nevertheless, the stocks have fallen -42.00% over the past one year. While a 52-week high of $17.80 was reached on 02/13/25, a 52-week low of $4.71 was recorded on 01/16/25. SMA at 50 days reached $5.94, while 200 days put it at $10.73.
Levels Of Support And Resistance For ENTA Stock
The 24-hour chart illustrates a support level at 6.92, which if violated will result in even more drops to 6.70. On the upside, there is a resistance level at 7.52. A further resistance level may holdings at 7.90. The Relative Strength Index (RSI) on the 14-day chart is 69.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.36, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 24.64%. Stochastics %K at 83.94% indicates the stock is a selling.
How much short interest is there in Enanta Pharmaceuticals Inc?
A steep rise in short interest was recorded in Enanta Pharmaceuticals Inc stocks on 2025-01-31, growing by 17172.0 shares to a total of 3.36 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 3.35 million shares. There was a rise of 0.51%, which implies that there is a positive sentiment for the stock.
